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Abstract 
Cutaneous T cell lymphoma (CTCL) is a rare, incurable, chronic disease accounting for 
approximately 3% of non-Hodgkin’s lymphoma diagnoses every year.  Patients with CTCL have 
skin lesions that can vary in severity putting patients at risk for developing symptoms that may 
impair their quality of life (QOL).  The disease burden can lead to increased depressive 
symptoms, fatigue distress, and anxiety that the disease may be worsening.  Seventy-five 
participants agreed to take part in an exploratory, prospective study to evaluate depressive 
symptoms, anxiety, fatigue distress, and spirituality as predictors of QOL in CTCL patients.  
Demographic variables including stage of disease, ethnicity, age, gender, marital status, level of 
education, and time since diagnosis, were also included in the analyses to assess for 
relationships.  Bivariate correlations, t-tests, and regression analyses were conducted to assess 
for relationships among the predictor variables and QOL.  The analyses revealed that the 
proposed model explained 64% of the variance, and depressive symptoms (t= -2.4, p= 0.020) 
and stage of disease (t= -3.0, p= 0.004) significantly predicted the QOL of CTCL patients.  
Evaluating for predictors that influence the QOL helps us to better understand the needs of the 
patients afflicted with CTCL.  The importance of studying the QOL of the CTCL patients lies in 
the fact that nurses can assist in helping patients alleviate some of the symptoms they 
experience, thereby improving their QOL.  Further study is warranted in developing 
interventions to assist in the preservation of QOL. 
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Chapter I:  Introduction 
Cutaneous T cell lymphoma (CTCL) is a malignancy characterized by the presence of a 
clonal T lymphocyte population in the skin and affects the largest, most visible organ that we 
possess, the skin.  CTCL may initially present with patch or plaque lesions on the skin, which 
tends to resemble psoriatic lesions.  In the United States, approximately 16,000 to 20,000 
people are currently living with a diagnosis of CTCL.  In addition, approximately 1200 new cases 
of this disease are diagnosed each year (Demierre, Gan, Jones, & Miller, 2006; Sampogna, et 
al, 2009).  Like psoriasis, CTCL is chronic, indolent in nature, and has complex pathophysiology 
involving the manifestations of a dysfunctional immune system primarily affecting the skin 
(Kimball, Jacobson, Weiss, Vreeland, & Wu, 2005; Pereira, Brito, & Smith, 2011).  This disease 
causes itchy, painful, flakey, and erythematous skin that can significantly impact the quality of 
life in affected patients.  It has also been known to have a higher incidence in men than women 
and is typically diagnosed in older patients (Kim & Hoppe, 1999). Patients with a diagnosis of 
CTCL are part of a small population that suffers from a chronic, incurable disease. 
Clinical manifestations may imitate indolent, non-malignant conditions; therefore, 
obtaining a biopsy is important in confirming the diagnosis of CTCL.  The specimen undergoes 
morphologic and immunohistochemical evaluation.  The observed infiltrate consists of both CD4 
positive (+) and CD8 positive (+) T cells, more specifically clonal CD4+ CD45RO positive (+) 
skin homing cells (Demierre et al, 2006; Wong, Mishra, Hake, & Porcu, 2011).  The diagnosis of 
CTCL is further supported by an increased ratio of CD4+ to CD8+ T cells, TCR clonality, and 
loss of surface antigens such as clusters of differentiation 5 (CD5), CD7, and CD26.  
Morphological features such as exocytosis, epidermotropism, and Pautrier’s microabscess may 
2 
also be present (Wong et al, 2011).  Microscopic and immunophenotypic evaluation of Pautrier’s 
microabscess demonstrate that they are intraepidermal collections of malignant T lymphocytes 
that are in close proximity to dendritic cells also known as Langerhan’s cells.  From this 
information came the hypothesis that cytokines released from the Langerhan’s cells recruit 
malignant CD4+ cells to the epidermis.  This cross talk may also be important for disease 
progression (Wong et al, 2011). 
Histopathology reveals infiltration of reactive CD8+ and malignant CD4+ T cells, with a 
dominance of T helper cell type 1 (TH1) cytokine patterns in early stages, with a gradual shift 
to the predominance of CD4+ T cells and T helper cell type 2 (TH2) skewing in advanced stages 
of CTCL (Wong et al, 2011).  This suggests that the loss of CD8+ mediated immune response 
may parallel the progression of disease.  
  Staging of disease is imperative for determining treatment and prognosis. Complete 
physical examination to assess the percentage of body surface area that is involved is 
imperative.  Recommendations also include laboratory studies, viral studies to include Epstein-
Barr Virus (EBV) and cytomegalovirus (CMV) by Polymerase Chain Reaction (PCR), hepatitis 
panel, Human Immunodeficiency Virus (HIV) 1 & 2, and human T lymphocyte virus (HTLV) 1 & 
2. Positive Emission Topography (PET) and Computed Topography (CT) scans upon initial
evaluation will show the presence or absence of lymphadenopathy and/ or organomegaly and 
should be obtained.  Bone marrow biopsy should be performed if systemic disease is suspected 
(NCCN, 2012).  Staging has been presented by the National Comprehensive Cancer Network 
(Tables 1 & 2). 
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Table 1. 
 
 
 
 
TNMB TNMB Classification and staging of Cutaneous T Cell Lymphoma 
Skin               
                     T1 
                     T2 
                     T3 
                     T4 
 
Limited patches, papules and/or plaques covering <10% BSA 
Patches, papules and/or plaques covering >10% BSA 
One or more tumors (>1 cm in diameter) 
Confluence of erythema >80% BSA 
Node            
                     N0 
                     N1 
                     N2 
                     N3 
                     NX 
 
No clinically abnormal peripheral lymph nodes; biopsy not required 
Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 
Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 
Clinically abnormal peripheral lymph nodes; histopathology Dutch or 3-4 
Clinically abnormal peripheral lymph nodes; no histologic confirmation 
Visceral       
                       M0 
                       M1 
 
No visceral organ involvement 
Visceral involvement( must have pathology confirmation and organ should be specified) 
Blood            
                        B0 
 
                        B1 
                        
                        B2            
                       
 
Absence of significant blood involvement: <5% of peripheral blood lymphocytes are 
atypical (Sezary) cells. 
 
Low blood tumor burden: >5% of peripheral blood lymphocytes are atypical (Sezary) cells 
but does not meet the criteria of B2 
High blood tumor burden: >1000mcl Sezary cell 
 4 
 
Table 2.  Staging for Cutaneous T-cell Lymphoma.   
 T N M B 
IA 
IB 
1 
2 
0 
0 
0 
0 
0, 1 
0, 1 
IIA 
IIB 
1-2 
3 
1, 2 
0-2 
0 
0 
0, 1 
0, 1 
IIIA 
IIIB 
4 
4 
0-2 
0-2 
0 
0 
0 
1 
IVA 
IVA 
IVB 
1-4 
1-4 
1-4 
0-2 
3 
0-3 
0 
0 
1 
2 
0-2 
0-2 
 
Cytokine profiles performed on lesional skin from patients representing all stages of 
disease have provided clues to the changes in the microenvironment during progression of 
CTCL (Wong et al, 2011).  Normal to increased expression of interleukin-2 (IL-2), interleukin-12 
(IL-12), and interferon gamma (IFNG), a normal T helper cell type 1 (TH1) cytokine pattern, is 
observed in early stage CTCL.  Decreased IL-2, IL-12, and IFNG demonstrate a loss of TH 1 
cytokines and an increase in interleukin-4 (IL-4), interleukin-10 (IL-10), interleukin-5 (IL-5), and 
interleukin-13 (IL-13) demonstrates an increase in T helper cell type 2 (TH 2) cytokines and is 
seen in late stages of CTCL.  Interleukin-5 has been associated with the recruitment of 
eosinophils and may play a role in the development of pruritis.  A pleotropic cytokine, 
interleukin-16 (IL-16), has recently been identified as a chemoattractant for CD4+ T cells.  The 
gradual loss of intracellular IL-16 in T cells is observed from CTCL stage IB and on.  The CD8+ 
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T cells share a TH 1 phenotype and play a role in cell-mediated immunity; their presence may 
be consistent with an anti-tumor response (Wong et al, 2011).    
    Apart from the detrimental physiological manifestations, numerous psychosocial 
consequences prevail given the disfiguring nature of CTCL; including negative self-image and 
altered perception of self by others (Sampogna et al, 2009).  While few studies have focused on 
CTCL, there have been studies on psoriasis, a similarly disfiguring disease.  Studies have 
demonstrated that approximately 40% experience significant anxiety, 38% experience high 
levels of worry, 10% of patients with psoriasis experience clinical depression, and 10% 
experience suicidal ideation (Gupta, Schork, Gupta, & Ellis, 1993; Gupta, Gupta, Schork, & Ellis, 
1994; Fortune, Richards, Main, & Griffiths, 2000; Richards, Fortune, Griffiths, & Main, 2001).  
The impact of a disfiguring disease, such as psoriasis, on quality of life has been described as 
similar to other chronic diseases, to include cancer, arthritis, and depression (Rapp, Feldman, 
Exum, Fleischer, & Reboussin, 1999).   
There have been limited studies assessing the quality of life in CTCL patients.  Two 
studies have examined the psychological and social issues in CTCL patients using the Health 
Related Quality of Life (HRQoL) instrument and the SkinDex-29 measurement tool (Sampogna 
et al, 2009; Demierre, et al, 2006).  Together, these studies established that patients suffer 
significant emotional distress related to the visibility of the disease, painful, itching skin, and 
worry about the prognosis of the cancer diagnosis.  CTCL is an incurable disease that has a 
profound effect on patients’ lives about which we know little.  This disease can be devastating 
and the impact on quality of life is as important as the outcome of treatment (Djulbegovic, 
1997).  CTCL can be a disfiguring disease with significant consequences affecting the 
psychological and emotional status of the patients, as well as their ability to form or maintain 
interpersonal relationships.  Social rejection, fear of contagion, or avoiding touch is a situation 
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that a person with a chronic skin condition may encounter (Sampogna et al, 2009).  In addition, 
distorted body image may lead to altered self-perception and dysfunctional intimate 
relationships (Sampogna et al, 2009).  These issues have not been explored in CTCL patients. 
Treatment of CTCL is determined based on the stage of disease at initial presentation.  
Skin directed therapies are the treatment of choice in patients with stage IA to IIA disease 
(Huber, Staib, Pehamberger, & Scarfetter-Kochanek, 2006; Gardner, Evans, Musiek, Rook, & 
Kim, 2009).  These therapies may include topical corticosteroids, topical retinoids (e.g. 
Bexarotene), phototherapy or any combination of these options.  In patients with stage IA 
disease that is refractory to topical treatment or progresses on skin directed therapy, the 
addition of a systemic treatment may increase the response rate (Huber et al, 2006).  Patients 
initially diagnosed with stage IIB or higher disease will be treated with more aggressive, 
systemic treatment with or without skin directed therapy (Gardner, Evans, Musiek, Rook, & Kim, 
2009).  Systemic treatment can come in the form of oral biologic modifiers, immunotherapy, 
intravenous chemotherapy, or intravenous biologic therapy.  Once patients have achieved a 
response, identified by a decrease in the amount and visibility of cutaneous lesions, tapering 
the treatment regimen or providing maintenance therapy is essential in optimizing duration of 
response (Prince, Whittaker, & Hoppe, 2009). 
If they achieve good control of their disease, patients with CTCL may live as long as 
their normal age matched controls (Demierre et al, 2006).  Improving their quality of life may 
profoundly impact the patient’s ability to cope with the diagnosis of an incurable disease and 
encourage patients to take an active part in managing the symptoms of their disease.  
Assessing the predictors of quality of life in patients with CTCL will form a solid foundation for 
future intervention studies to improve the control of the symptoms they experience. 
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Statement of the problem 
 Patients with CTCL may experience profound emotional and physical pain related to their 
disease, about which little is known.  The areas of affected skin can become significantly pruritic 
and painful.  In some cases these manifestations can involve greater than 80% of the body 
surface area.  Little research has focused on the quality of life in patients with CTCL although it 
is known to be an incurable, chronic disease.  Understanding the predictors of QOL might lead 
to better management of disease symptoms, thus improving the quality of life.  
Study of purpose 
 The purpose of this study was to evaluate predictors of quality of life of patients with 
CTCL.  Information gathered from surveys evaluating depressive symptoms, anxiety, spiritual 
well-being, fatigue distress, and the frequency and severity of cutaneous issues may be 
beneficial in evaluating the psychosocial and physical consequences of CTCL and how it 
influences quality of life.  The information will also be the foundation on which to design future 
intervention studies and guide clinical practice.   
Specific Aims 
The specific aims of this descriptive, exploratory, prospective study are to: 
1. Examine the factors that may predict the quality of life of patients with CTCL.  
2. To evaluate the psychosocial burden (depressive symptoms, anxiety, spiritual well-
being, and fatigue distress) of CTCL. 
3. Examine the influence of depressive symptoms, anxiety, fatigue distress, time since 
diagnosis, spiritual well-being, selected demographic variables including age and 
gender on the quality of life in patients with CTCL.   
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4. To correlate the data obtained from the Skindex-29 and the Skindex-16 to evaluate
the relationship between the two instruments and identify the most appropriate 
measurement tool for the given population. 
Definition of Relevant Terms 
Depressive Symptoms:  The impairment of the ability to appreciate the pleasures of life. 
Feeling sad or “down in the dumps”, easy to cry even at the smallest issues, everything appears 
bleak and hopeless, or a person feels that he or she will never be normal again (DSM IV, 2004).  
Spiritual well-being: A feeling of contentment and peace that arises from relationships with self, 
others, and a higher power, such as god.  (Burkhardt, 1989). 
Fatigue: “a distressing persistent, subjective sense of tiredness or exhaustion related to cancer 
or cancer treatment that is not proportional to recent activity and interferes with usual 
functioning” (NCCN, 2012). 
Fatigue Distress: distress or bother caused by fatigue or tiredness (Holley, 2000). 
Anxiety: A natural response and a necessary warning adaptation in human beings that can 
become a pathologic disorder when excessive.  It may, or may not, have a specific external 
stimulus, and can manifest physical and affective symptoms as well as changes in behavior and 
cognition. (DSM-IV, 2004). 
Quality of Life:  A complex concept that may be affected by an individual’s level of 
independence, psychological state, environment, social relationships, and physical health. 
(WHOQOL Group, 1993b). 
Significance to Nursing 
Care of the patient with Cutaneous T cell lymphoma focuses on management of 
distressing symptoms including, but not limited to, pruritis, pain, fatigue, and insomnia 
(Sampogna et al, 2009).  As the disease progresses, symptoms become more severe and more 
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prevalent.  The primary goal is to alleviate suffering and achieve optimal symptom management 
for patients experiencing this rare disease.  Evaluating for predictors of quality of life in patients 
with cutaneous T cell lymphoma will provide insight into what symptoms are the most 
distressing and have the most impact on quality of life for these patients.  Identifying the most 
distressing symptoms will allow us to focus future interventions on improving management of 
those symptoms, thereby improving the quality of life for our patients.  
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Chapter II:  Review of the Literature 
 This chapter reviews and synthesizes the current literature of cutaneous T cell 
lymphoma.  A search was conducted utilizing MEDLINE, PubMed, PSYCHinfo, and CINAHL to 
explore the literature regarding the quality of life in patients with CTCL.   Keywords such as, 
“quality of life”, “Cutaneous T cell lymphoma”, “psoriasis”, “depression”, and “body image” were 
used to guide the search.  All years and all designs were included.  Manual searches of 
references were conducted to identify pertinent studies to include in the literature review.  
Peer reviewed articles were assessed for scientific rigor and relevance to the current 
study.  The theoretical framework is discussed followed by a synthesis of the current knowledge 
about depressive symptoms and the role of each variable in the development of depressive 
symptoms.  Finally, the knowledge gaps where additional research is needed are identified. 
Theoretical Framework 
Maintaining good quality of life is important for patients with CTCL as their disease can 
cause unsightly skin manifestations, pain and itching, which in turn, can cause alterations in 
body image (Sampogna et al, 2009; Demierre et al, 2006).  The symptoms of the disease can 
also alter the maintenance and/or development of interpersonal relationships (Sampogna et al, 
2009).  The concepts represented in the model, provide a foundation for enhancing the quality 
of life for patients with an incurable, chronic disease. 
The conceptual model used in guiding this study (Figure 1) represents the suggested 
influence that demographic data such as age, gender, and ethnicity have on quality of life.  The 
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model also represents how psychological symptoms such as depression, spiritual well-being, 
fatigue, and anxiety and physical symptoms of the disease are related to the quality of life. 
 
 
      
       
 
 
      
      
 
 
Figure 1. Conceptual Model for the Study 
Psoriasis 
Psoriasis, also considered a disfiguring skin disease, negatively affects quality of life in 
CTCL patients.  Many cases of CTCL will present with lesions resembling psoriasis that may 
result in misdiagnosis until there is a lack of response to treatment or a progression of disease.  
Perrott and colleagues (2000) conducted an observational study to evaluate the relationships 
among physician ratings of physical severity, participant self-ratings of quality of life, and 
feelings of stigmatization in 101 patients with psoriasis (Perrott, Murray, Lowe, & Mathieson, 
Demographic 
 
 
 
 
 
 
 
 
 
 
 
 
Physical and Psychological 
wellbeing 
Depression; Anxiety; Spiritual well-
being; Fatigue; pain, burning, 
itching; and other skin symptoms 
 
Quality of Life 
Physical 
Role 
Social 
Cognitive 
Emotional 
 
Ethnicity 
Age 
Gender 
Level of 
education 
Race 
Marital status 
Stage of disease 
Time since diagnosis 
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2000).  The psoriasis area and severity index (PASI) was rated by a dermatologist working in 
the clinic and three questionnaires were administered to patients receiving psoralen and 
ultraviolet (PUVA) light therapy for their psoriasis.  The participants responded to seven pairs of 
questions to assess the overall quality of life.  These questions addressed the level of distress, 
disruption to daily routine, disruption to social life, general impact of psoriasis, and perceptions 
of others noticing the disease.  Participants also completed a 33-item stigmatization scale and 
answered questions related to vignettes designed to assess perceptions of prejudice, upset, 
discrimination, and embarrassment facing the participant.  Participants whose disease 
manifested at a younger age expressed more feelings of stigmatization as compared to older 
patients with comparable disease severity.  On the contrary, older participants reported greater 
psychosocial impact, as they perceived more negative impact in how they were viewed by 
others but did not feel stigmatized (Perrott et al, 2000).  
Approximately two-thirds of patients with psoriasis report the disease has a negative 
impact on their everyday life and this approaches 80% in patients with severe disease (Weiss, 
Kimball, & Liewehr, 2002; Krueger, Koo, & Lebwohl, 2001).  Weiss et al. (2002) conducted a 
descriptive, prospective study consisting of 35 consecutive patients.  Patients completed self-
administered questionnaires including Satisfaction with Life Scale (SWLS), Euro-QOL (EQ-5D), 
and the Medical Outcomes Study Short Form 36 (SF-36).  Psoriasis Area and Severity Index 
(PASI) was completed by two dermatologist investigators and the Self Assessed PASI (SAPASI) 
was completed by the participants.  They found that 23% of patients altered their career choice 
due to the impact of their disease and 6% reported that they were ‘often’ or ‘always’ depressed 
due to their condition.  In populations with chronic, disfiguring, and uncomfortable diseases, 
suicide is a concern (Weiss et al, 2002).   
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In secondary analysis of several observational studies Gupta and Gupta (1998) 
conducted a descriptive, observational study of 450 patients using the Carroll-Rating Scale for 
Depression (CRSD).  They reported that 9.7% of patients experienced suicidal ideation with 
5.5% experiencing it at the time of the study.  Suicidal ideation was associated with higher 
depression scores and higher self- rating of disease (Gupta & Gupta, 1998).  
Gelfand, Feldman, Stern, Thomas, Rolstad, and Margolis (2004) conducted a study 
evaluating the use of a comprehensive questionnaire to describe the determinants of quality of 
life in psoriasis patients.  Gelfand and colleagues found that as skin involvement with psoriasis 
becomes more extensive, patients suffer more impairment in their quality of life.  They also 
reported a weak negative correlation with quality of life and age, thereby identifying younger 
patients as being more impaired than older patients.  In fact, young female patients were more 
impacted by their disease (Gelfand et al, 2004). 
The studies evaluating quality of life in patients with psoriasis revealed that quality of life 
was better for patients in the later years of life.  The studies also emphasize how the 
appearance of their skin influences decisions to participate in social activities and the types of 
careers that were chosen.  Patients suffering with a chronic, visible disease may avoid social 
situations leading to a tendency to withdraw from society resulting in isolation, thereby 
increasing the presence of depressive symptoms.  Patients with a diagnosis of indolent cancer 
experience a good quality of life when the symptoms of disease are minimal.  Identification of a 
population that may need additional psychological support would allow health care providers to 
assist the patient to achieve and maintain a good quality of life. 
Quality of Life in Patients with Cutaneous T Cell Lymphoma 
There is limited research evaluating the quality of life in CTCL patients. Sampogna and 
colleagues (2009) conducted an observational, cross-sectional study to evaluate the 
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psychological distress and health related quality of life in 71 CTCL patients.  Participants 
completed the Skindex-29, and EORTC QLQ-C30 questionnaires to assess their quality of life.   
The results demonstrated that the presence of the disease affected social interactions and 
intimacy with loved ones.  They also found that impairment in global health status, emotional 
well-being, fatigue, and insomnia were worse in patients with advanced stage disease 
(Sampogna, et al, 2009).   
Demierre and colleagues (2006) evaluated the quality of life of 630 CTCL patients 
(Demierre, Gan, Jones, & Miller, 2006).  A four page self-administered questionnaire was mailed 
or completed online by patients who were members of the United States Mycosis Fungoides 
Foundation. The study was designed to evaluate patients’ perspectives regarding the impact of 
CTCL and its treatment.  Results demonstrated that 62% of participants reported they felt 
unattractive due to their disease.  Respondents also noted that they felt ashamed of their 
disease when it was mistaken for a contagious condition.  Greater than 80% of participants felt 
bothered by the itching, scaling, and skin redness.  The disruption in the lives of CTCL patients 
was attributed to fatigue (66%) that resulted in days missed from work or school, and 43% 
stated that they felt they couldn’t provide for their families.  Limitations of this study included 
that some patients have limited access to health care and may not know of the United States 
Mycosis Fungoides Foundation (Demierre et al, 2006).   
A smaller quality of life study was conducted by Demierre, Tien, and Miller (2005).  This 
was a monocenter, cross-sectional study and consisted of 22 patients with CTCL with stage of 
disease ranging from IA to IVB.  Ten patients had stage IA to IIA disease and 12 patients 
exhibited late stage disease (IIB-IVB).  Mean age of participants was 63 years, majority of 
participants were white, and there were equal numbers of male and female participants.  All 
participants completed a general HRQoL instrument (FACT-G) and a disease specific HRQoL 
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instrument (Skindex-29).  They found that participants with higher stage disease reported a 
worse quality of life.  Even participants with lower stage of disease reported alterations in their 
quality of life, and this became more pronounced as the disease progressed.  Demierre et al. 
(2005) also reported that the impact of CTCL on functioning appeared to be similar to studies 
conducted for participants with psoriasis assessed utilizing the Skindex-29 questionnaire.  Of 
note, the emotional status of CTCL participants was not as affected as was reported in the 
psoriasis participants although this may be attributed to the difference in the age of the 
participants, as psoriasis usually affects a younger population. A limitation of this study was the 
very small sample size (Demierre et al, 2005).   
Duvic et al (2001) conducted a study to evaluate the effects of oral Bexarotene in 
patients with CTCL.  The patients completed a general (Spitzer) QOL questionnaire and a non-
validated CTCL specific QOL questionnaire once monthly for four months.  A total of 94 patients 
with a confirmed diagnosis of CTCL were enrolled.  The QOL scores did not change significantly 
throughout the study.  The CTCL specific QOL instrument showed significant improvement in 
the symptoms from baseline to end of study.  The results showed that pruritis improved from 
moderate to mild and satisfaction with appearance improved from moderately dissatisfied to 
neutral.  Notably, the patients who received treatment with oral bexarotene reported better 
quality of life assessments even if they were considered non-responders to the medication 
(Duvic et al., 2001). 
More recently, a study was conducted by Wright and colleagues (2013) to evaluate the 
prevalence and severity of pruritis and quality of life in patients with cutaneous T cell lymphoma 
(Wright, Wijeratne, Hung, Gao, Whittaker, Morris, Scarisbrick, & Beynon, 2013).  They recruited 
100 patients for participation in the study.  Patients who met eligibility criteria completed the 
skindex-29 and the visual analogue scale for itch (VASitch).  The Skindex-29 consists of 30 
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questions with one question not included in the analysis.  Of the participants, 88% reported 
itching with 46% of these stating that it was often or always problematic.  This study was 
effective in evaluating the presence of pruritis in the study participants; however, this patient 
population experiences a myriad of symptoms that were not assessed in this study (Wright et 
al., 2013). 
There have been no studies conducted to evaluate spiritual well-being in CTCL patients.  
Research investigating spiritual well-being in patients with chronic, incurable, cancer, revealed 
negative correlations between spiritual well-being and ineffective coping styles such as 
avoidance, helplessness, and hopelessness (Cotton, Levine, Fitzpatrick, Dold, & Targ, 1999; 
Nelson, Rosenfeld, Breitbart, & Galietta, 2002; Krupski, Kwan, Fink, Sonn, Maliski, & Litwin, 
2006; Bredle, Salsman, Debb, Arnold, & Cella, 2011).  Whereas, positive spiritual well-being 
played an important part in effective coping and increased patient’s QOL (Dapueto, Servente, 
Francolino, & Hahn, 2005; Whitford, Olver, & Peterson, 2008).   
 In summary, only limited research has been reported about the QOL of patients with 
cutaneous T cell Lymphoma, and with one exception, those studies have had small sample sizes 
and none has focused on predictors of quality of life in this patient group.  The negative effect 
of depressive symptoms, fatigue, and anxiety, on QOL has been documented in patients with 
cancer (Butow, Coates, & Dunn, 1999).  In patients with advanced cancer, spiritual well-being 
has been identified as an important factor in alleviating depressive symptoms, decreasing 
anxiety, and preserving or restoring good QOL (Tate & Forchheimer, 2002; Bredle, Salsman, 
Debb, Arnold, & Cella, 2011; Daugherty et al, 2005).  Future research should investigate the 
physical symptoms, depressive symptoms, anxiety, fatigue distress, and spiritual well-being as 
factors that influence QOL in this special population.  Further research is needed using a larger 
and more diverse sample. 
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Chapter III: Methods 
This chapter discusses the design of the study, sample selection including inclusion and 
exclusion criteria, and the setting for the study.  The measurement instruments that were used 
in the study are described and psychometric properties are delineated. The procedures for 
institutional approval, informed consent, and the analysis of the data are also described.  This 
was a descriptive, exploratory, prospective study designed to examine the predictors of quality 
of life in patients with CTCL.   
Institutional approvals 
The Moffitt Scientific Review Committee (SRC) and the USF Institutional Review Board 
(IRB) received submissions of the protocol for their review.  Written approval was obtained 
from both organizations and the study began in February, 2013 (Appendix A).  The study took 
place at Moffitt Cancer Center & Research Institute in Tampa, Florida and was conducted over a 
seven month period.   
Setting and Sample 
CTCL participants were referred to the study from the cutaneous T cell lymphoma and 
the malignant hematology clinics at Moffitt Cancer Center between February 2013 and 
September 2013.  Following approval by the Moffitt SRC and the USF IRB, access to the 
participants was based on referral by the physicians, nurses, and the manager in the cutaneous 
clinic at Moffitt Cancer Center.  Seventy-five patients who had a confirmed diagnosis of CTCL 
were recruited for participation in the study.  Inclusion criteria were:  being able to read and 
understand English, being 18 years or older, and being alert and able to provide informed 
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consent.  Exclusion criteria included minor children, patients with other new diagnoses of cancer 
within one year, and patients with altered mental status who were unable to provide consent.  
Participants were informed that the data will be de-identified and will remain anonymous.   
Measures 
 The measures that were used in this study are described below.  The individual scales 
are appended (Appendix B). 
 Quality of life 
The Quality of Life Core Questionnaire of the European Organization for the Research 
and Treatment of Cancer (EORTC QLQC-30) was used to measure CTCL patients’ QOL.  This 
instrument consists of 30 items arranged within six scales of aspects of functioning (Dirmaier, 
Zaun, Koch, Harfst, & Schulz, 2004).   These scales included physical (Cronbach’s alpha 0.72-
0.86), role (Cronbach’s alpha 0.83-0.91), social (Cronbach’s alpha 0.74-0.86), cognitive 
(Cronbach’s alpha 0.56-0.70), and emotional functioning (Cronbach’s alpha 0.69-0.87), and 
global quality of life (Cronbach’s alpha 0.81-0.93).  In addition, the scale consisted of three 
symptom subscales, fatigue (Cronbach’s alpha 0.79-0.84), nausea/vomiting (Cronbach’s alpha 
0.60-0.77), and pain (Cronbach’s alpha 0.73-0.76), and six symptom items including financial 
problems, constipation, diarrhea, dyspnea, sleep disorder, and loss of appetite.  Items are 
measured on a four-point Likert type scale.  The scores of the six functioning scales were 
calculated by adding up the raw scores of a scale and dividing by the number of items on that 
scale.  The scores were mapped for each parameter onto a scale of zero-100, with 100 
representing the highest level of functioning.  The symptom scales were calculated in a similar 
fashion with the exception that higher scores indicated a higher symptom burden.  For the 
purposes of this study, only the total score was used in the analyses.  Cronbach’s alpha for the 
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EORTC QLQ-C30 version 3, has been reported to be greater than 0.70, representing acceptable 
internal consistency (Dirmaier et al., 2004). 
Dermatology related quality of life 
The Skindex-29 is a disease specific instrument used to measure the effects of 
dermatological disease on the quality of life in CTCL patients.  This instrument is a 29-item 
questionnaire focusing on three dimensions: Symptoms (seven items), emotions (10 items), and 
functioning (12 items).  The Skindex-29 is a five point Likert type scale.  The overall score, as 
well as the individualized scores for each dimension are converted to a scale of zero (no impact 
on QOL) to 100 (maximum impact on QOL).  Internal consistency reliability has ranged from 
0.86-0.95 (Chren, Lasek, Flock, & Zyzanski, 1997). 
The Skindex-16 is a shortened version of the Skindex-29, addressing 16 questions that 
measure bother rather than frequency of symptoms.  It is because of this difference the 
SkinDex-16 and SkinDex-29 will be evaluated to determine if one instrument is superior for use 
in this specific population.  The SkinDex-16 is scored on a bipolar scale with seven response 
choices ranging from “never bothered” to “always bothered”.  There are three subscales 
consisting of symptoms, emotions, and functioning.  Scores range from zero-100 and internal 
reliability has been demonstrated with a Cronbach’s alpha of 0.86-0.93 (Chren, Lasek, Sahay, & 
Sands, 2001).  
Depressive Symptoms 
The Center for Epidemiologic Studies Depression (CES-D) scale is a widely used self-
report instrument to measure depressive symptoms.  The CES-D consists of 20 items and is 
purported to measure important components of depressive symptoms including feelings of 
helplessness and hopelessness, feelings of guilt and worthlessness, depressed mood, 
psychomotor retardation, loss of appetite, and sleep disturbances.  There are 20 items that 
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have been clustered into four dimensions 1) depressed affect 2) positive affect 3) somatic-
retarded activity and 4) interpersonal relations (Radloff, 1977).  Scores on the CES-D can range 
from zero-60. Although the CES-D does not diagnose depression, a total score of 16 or higher 
requires further screening for major depression, and a score greater than 23 may indicate 
probable depression.  Cronbach’s alpha for the CES-D has been reported to be greater than 
0.80 representing good internal consistency (Schroevers, Sanderman, Sonderen, & Ranchor, 
2000). 
Anxiety 
The state-trait anxiety inventory is an instrument commonly used to measure state and 
trait anxiety (Spielbeger, Gorsuch, Lushene, Vagg, & Jacobs, 1983).  The Y form consists of 20 
items evaluating state anxiety and 20 items evaluating trait anxiety.  All items are scored on a 
four point Likert-type scale, from “almost never” to “almost always”.  High levels of anxiety are 
indicated by higher scores.  Internal consistency coefficients range from 0.86 to 0.95 
(Spielberger et al., 1983).  Only the state anxiety inventory will be used in this study. 
Spiritual Wellbeing 
The Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being scale (FACIT-
SP) was developed to address the need for a broad measure of spiritual well-being (Cella, 
Tulsky, Gray, Sarafian, Linn, et al., 1993).  This is a 12 item measurement tool consisting of 
three subscales (peace, meaning, and faith).  This is a self-administered, five point Likert-type 
scale that measures distress and is scored on a zero (not at all) to four (very much) scale. 
Higher scores represent greater spiritual well-being.  This measurement tool has been validated 
in cancer patients and patients receiving hospice services.  The Cronbach’s alpha coefficient for 
the 12 item instrument has been reported to be 0.81-0.88 (Cella, et al. 1993; Bredle, et al, 
2011). 
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Cancer Related Fatigue 
Cancer Related Fatigue Distress Scale (CRFDS) evaluates the distress experienced by 
patients who suffer from the symptom of fatigue (Holley, 2000).  The instrument consists of 20 
items and encompasses the cognitive, psychological, physical, social, and spiritual domains.  It 
is scored on an 11 point Likert type scale, zero (no distress) to 10 (severe distress).  The scores 
are summed and range from 0-200 with higher scores indicating a higher level of fatigue 
distress.  There are three additional questions rating fatigue at the time of completion of the 
survey, worst fatigue over the past week and usual amount of fatigue.  There are three 
additional questions addressing level of fatigue over the past week, usual level of fatigue, and 
level of fatigue now.  The CRFDS has an alpha coefficient of 0.98 (Holley, 2000). 
Demographic form 
Demographic data was obtained to describe the characteristics of the sample.  The 
investigator developed demographic form constructed for the study included gender, race, age, 
marital status, type and stage of disease, time since diagnosis, religious affiliation, and level of 
education.  
Procedures 
After the protocol was approved by the Moffitt SRC and the USF IRB, physicians began 
to refer patients who were identified as eligible for participation.  Once referred, the patients 
underwent further screening by the investigator to confirm eligibility.  Following confirmation of 
eligibility, patients were approached for participation.  The patient was escorted to an exam 
room in the cutaneous or the hematology clinic to ensure privacy and confidentiality.  The 
consent and protocol of the study was explained in detail and questions were answered to the 
patient’s satisfaction.  If the patient consented to participation, one copy of the consent 
remained in the research folder and the patient received a copy of the consent.  Data collection 
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began with administration of the Skindex-29, QLQ-C30, CES-D, STAI, FACIT-Sp, cancer related 
fatigue distress scale, Skindex-16, and the demographic form.  Completion of these forms 
completed the patient’s participation in the study. 
Analysis of data 
All data was analyzed using SPSS version 21 statistical software (IBM, Somers, NY).  To 
analyze demographic data, descriptive statistics were used including means, standard 
deviations, frequencies and percentages.  All multi-item instruments were evaluated for internal 
consistency and reliability and alpha coefficients were obtained.  To meet the specific aims, the 
following analyses were conducted: 
1. To examine factors that may predict the quality of life of patients with CTCL, means and
standard deviations were calculated for the EORTC QLQ C-30, Skindex-29 and Skindex-
16. 
2. To evaluate the psychosocial burden (depression, anxiety, fatigue, and spiritual well-
being) of CTCL, means and standard deviations were calculated for the STAI, CES-D, 
CRFDS, and FACIT-Sp.  
3. To examine the influence of depression, anxiety, time since diagnosis, selected
demographic variables including age and gender, as predictors of quality of life of CTCL, 
were calculated using multiple regression analysis. 
4. To compare the Skindex-29 and the Skindex-16, convergent validity was assessed using
Pearson’s correlation coefficient.  
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Chapter Four: Results 
This chapter presents the results of the study. First the sample is described; this is 
followed by means and standard deviations for all of the measures used in the study. Finally, 
specific aims are addressed. 
Sample 
The sample consisted of 75 participants, with slightly more men than women, all with a 
confirmed diagnosis of cutaneous T cell lymphoma.  The majority of participants were 
diagnosed with stage IA, IB, or IIA disease.  The majority of the patients were white, married, 
and had a Christian religious affiliation (Table 3). The age of the participants ranged from 24 to 
88 years of age, with a mean of 62.5 years and a standard deviation of 14.6.  The range of 
years of education was 10 to 24 years.  Of the participants, 22 (29.3%) had at least some high 
school education and most (N=53, 70.5%) had college education (Table 4).  
Table 3. Frequencies and Percentages of the Demographic Variables of the Sample 
(n=75). 
Variable Frequency Percent 
Gender 
   Male        41     54.7 
   Female        34     45.3 
Ethnicity 
   White         54     72 
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Table 3 (continued)  
  Black        16     21.3 
   Hispanic          5  6.7 
Stage of Disease 
   IA        24    32 
   IB        19    25.3 
   IIA          4      5.3 
   IIB          8   10.7 
   IIIA          2      2.7 
   IIIB          6      8.0 
   IVA        10    13.3 
   IVB          1      1.3 
Marital status 
   Married         51     68 
   Single         12     16 
   Widowed 6       8 
   Divorced 6       8 
Religion 
   Non-Catholic Christian         44     58.7 
   Catholic         24     32.0 
   Jewish 3       4 
   None  2       2.7 
   Muslim 1       1.3 
   Other, non-specified  1       1.3 
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Table 4. Mean, Standard Deviations, and Range for Demographic Variables of the Sample 
(n=75). 
Variable Mean Range      SD 
Age 62.5 (24-88)  14.6 
Years of education  15.0 (10-24)  2.8 
Time since diagnosis   5.0   (1-31)   5.2 
Descriptive Data 
The means and standard deviations of depressive symptoms, anxiety, fatigue distress, 
and spiritual well-being scores are delineated in Table 5.  Also included are the mean and 
standard deviation of the outcome variable, quality of life. 
Table 5. Means and Standard Deviations of Patients’ scores on Quality of Life, Anxiety, 
Depressive Symptoms, Spiritual Well-being, and Fatigue Distress. (N=75) 
Variable Range       Mean SD 
Depressive symptoms  0-60  11.0  11.9 
Anxiety 20-80   34.7 14.6 
Fatigue distress  0-200  48.6   55.5 
Quality of life  0-100  68.9   22.4 
Spiritual well-being  0-156 118.5 30.2 
All instruments used in this study were tested for their reliability when utilized among 
this specific population of cutaneous T cell Lymphoma patients.  The Cronbach’s alpha 
coefficients were strong with all being greater than 0.70, and most of them being greater than 
0.90 (Table 6). 
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Table 6. Reliabilities of the Measurement Instruments 
Instrument Cronbach’s alpha 
Cancer related fatigue distress scale 0.99 
SkinDex-29  0.98 
SkinDex-16  0.96 
State anxiety 0.96 
CES-D  0.94 
EORTC QLQ-C30 0.92 
FACIT-Sp 0.77 
The items of the SkinDex-29 were evaluated for the rate of responses to each item 
(Table 7).  Responses included were “never”, “rarely”, “sometimes”, “often”, and “all the time”. 
Skin itching and skin irritation were the most frequently reported symptoms. The highest mean 
scores were found in the most frequently occurring symptoms. 
Table 7. Frequency, Percent, Means, and Standard Deviations of Responses to SkinDex-29 
Items 
Item Frequency   Percent    Mean        SD 
Skin itching  70         93   58.3   29.2 
Skin irritated    68      91   54.0 29.1 
Worry about severity       67      89  55.7 31.2 
Worry about progression      66      88  57.7  31.6 
Annoyed      64      85  50.7  32.4 
Skin sensitive       64      85  57.0  33.5 
Frustrated       63      84  51.7  33.0 
Depressed      51      68  34.7  32.9 
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Table 7 (continued) 
Disrupted sleep      51      68  38.0  34.7 
Skin pain      46      61  32.7  32.9 
Skin burns/stings      46      61  33.7  34.8 
Embarrassed    44      59  32.0  34.5 
Worry about scars      44      59  29.7  31.5 
Ashamed       43      57  30.7  33.8 
Tired        43      57  35.7  37.2 
Affects social life      42      56  31.7  35.0 
Angry       39      52  30.7  35.5  
Affects closeness to loved ones  39      51  23.0  28.7 
Affects work/hobbies  36      48  28.0  36.8 
Water bothers      36      48  27.0  34.6 
Affects interactions with others      36      48  25.0  31.6 
Affects desire to be with others      36      48  26.0  32.7 
Humiliated by skin      35      47  23.0  29.6 
Difficult showing affection       35      47  23.0  31.0 
Stay at home       34      45  25.3  34.3 
Do things alone      33      44  23.0  32.6 
Interferes with sex life      33      44  23.0  32.5 
Skin bleeds      31      41  18.7  26.7 
Influence of Predictor Variables on QOL 
The predictor variables that demonstrated a significant bivariate correlation with QOL 
were included in the regression analysis.  A spearman correlation was utilized in the evaluation 
of a relationship among stage of disease and quality of life.  The variables of stage of disease, 
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depressive symptoms, anxiety, spiritual well-being, and fatigue distress all demonstrated a 
significant P value of less than 0.001 (Table 8).  The correlations reveal that as the symptoms 
of depression, anxiety, and fatigue distress increase, the QOL decreases.  Also, because the 
SkinDex instruments demonstrate a negative correlation, this shows that as the cutaneous 
manifestations become worse patients experience worse QOL.  Spiritual well-being had a 
positive correlation with QOL, meaning that as spiritual well-being increases the QOL increases.   
Table 8. Correlation of Predictors with Quality of Life (n=75) 
Variable     r     P  
Stage of disease -0.450 <0.001 
Depressive symptoms -0.710 <0.001 
Anxiety -0.641 <0.001 
Spirituality  0.729 <0.001 
Fatigue distress -0.710 <0.001  
SkinDex-29 -0.644 <0.001 
SkinDex-16 -0.569 <0.001 
 
 Categorical variables were evaluated using an independent samples t-test (Table 9).   
Quality of life scores did not differ by ethnicity, marital status, or gender and thus, were not 
significantly related to QOL.  Therefore, these variables were omitted from the regression 
analysis. 
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Table 9. Independent Samples t-Test Results of Ethnicity, Marital Status, and Gender with QOL 
Variable   N  mean   t   P 
Ethnicity 
 White   54  71.1   -1.409   0.163 
 Non-white  21  63.1  
Marital status 
 Married  51  72.5   -1.909   0.064 
 Not married  24  61.1 
Gender 
 Male    41  72.6   1.578   0.119 
 Female   34  64.5 
 
 The subsequent regression analysis (Table 10) revealed that only depressive symptoms 
(CES-D) and stage of disease had a significant relationship with QOL.  More specifically, as the 
stage of disease increased, there was a decrease in the QOL.  Likewise, as the depressive 
symptoms increased the QOL decreased.  These results identify stage of disease and depressive 
symptoms as having statistically significant influences on the outcome, QOL.   
Table 10. Regression of Predictor Variables on QOL 
Variable                B          Standard error of B                     t                P 
Stage of disease         -11.028 3.719 -0.240   -3.0          0.004  
Depressive symptoms  -0.701 0.295 -0.373   -2.4          0.020 
Anxiety   0.204 0.243   0.133    0.8          0.404 
Spiritual well-being   0.189 0.142  0.255    1.3          0.187 
Fatigue distress  -0.024 0.069 -0.353    0.7         -0.060 
SkinDex-29  -0.105 0.117 -0.115    0.896     -0.374 
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Relationship Among the SkinDex-16, SkinDex-29, and the Predictor Variables 
To evaluate the relationship between the SkinDex-16 and Skindex-29, correlations were 
conducted among the subscales as well as the total scores for both.  The results of the 
correlations revealed a strong relationship among the subscales of each instrument and within 
each instrument as well as among the total scores of both instruments (Table 11). 
Table 11. Correlation of SkinDex-29 and SkinDex-16 Measurement Tools (n=75) 
Variablea      SD29E       SD29F  SD29S SD29T  SD16E   SD16F    SD16S SD16T 
SD29E  -   -  -  -  -  -  -  - 
SD29F  0.859*  -  -  -  -  -  -  - 
SD29S   0.702*  0.802*  -   -   -  -  -  - 
SD29T  0.926*  0.958*  0.895*  -  -  -   -  - 
SD16E  0.847*  0.732*    0.651*  0.805*  -   -   -  - 
SD16F  0.806*  0.857*   0.621*    0.825*  0.830*   -   -  - 
SD16S  0.563*  0.634*  0.781*    0.708*  0.747*   0.619*   -  - 
SD16T  0.815*  0.817*   0.755*  0.859*  0.949*  0.900*  0.870*  - 
aE, Emotions; F, Function; S, Symptoms; T, Total; *Significance <0.001 
Each predictor of fatigue distress, depressive symptoms, anxiety, and spirituality, the 
demographic variables of stage of disease, age, gender, ethnicity, and level of education, were 
correlated with the SkinDex-16 and SkinDex-29.  The results of the correlations with SkinDex-29 
revealed that as the cutaneous symptoms become worse, spiritual wellbeing decreases (Table 
12).  The correlations of significant predictor variables and SkinDex-16 are also presented in 
Table 12.  There were negative correlations noted between the SkinDex-16 and spirituality and 
SkinDex-16 and age.  This demonstrates that as participants age they were less likely to have 
or complain of cutaneous symptoms. 
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Table 12. Correlation of Individual Predictors with the SkinDex-29 and the SkinDex-16 
Correlation        SkinDex-29    SkinDex-16 
    r  P r P 
Anxiety 0.691  <0.001          0.697        <0.001 
Depressive symptoms 0.736 <0.001          0.636        <0.001 
Spirituality -0.744 <0.001         -0.705        <0.001 
Fatigue distress 0.787 <0.001          0.745        <0.001 
Stage of disease 0.281   0.007          0.251  0.015 
Age -0.327   0.002         -0.372          0.001 
Level of Education -0.258   0.013 -  - 
An independent samples t-test was conducted to evaluate the variables of ethnicity, 
gender, and marital status for the presence of a significant relationship with QOL (Table 13).  
Ethnicity and gender were significantly associated with both the Skindex-16 and the Skindex-29. 
Marital status did not demonstrate a significant relationship with the Skindex-16 and Skindex-
29.
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Table 13. Independent Samples t-Test Results of Ethnicity, Marital Status, and Gender with 
SkinDex-29 and SkinDex-16. 
Variable  N mean  t   P 
SkinDex-29 
Ethnicity 
White 54 44.7 2.108 0.038 
Non-white 21 31.8 
Marital status 
Married  51 32.9 1.309 0.195 
Not married 24 40.8 
Gender 
Male  41 27.3 -3.350 0.001 
Table 13 (Continued) 
Female 34 45.1 
SkinDex-16 
Ethnicity 
White 54 47.1 2.392 0.019 
Non-white 21 30.2 
Marital status 
Married  51 31.2 1.690 0.095 
Not married 24 42.9 
Gender 
Male 41 26 -3.163 0.002 
Female 34 45.6 
When the predictor variables were regressed onto the SkinDex-29, the variables of 
depressive symptoms, fatigue distress, and age revealed statistically significant relationships 
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(Table 14), indicating that these variables exhibit significant relationships with cutaneous 
symptoms. 
Table 14. Regression of Predictor Variables onto SkinDex-29 (n=75) 
Variable  B     Standard error of B       t          P 
Stage of disease  6.153 4.005  0.122   1.536  0.129 
Depressive symptoms  0.596 0.295  0.290  2.021  0.047 
Anxiety   -0.203  0.254  -0.121  -0.801  0.426 
Spirituality  -0.080  0.145  -0.098  -0.550  0.584 
Fatigue distress  0.204 0.067  0.463  3.055  0.003 
Age   -0.299  0.150  -0.178  -2.003  0.049 
Gender   5.619 3.639  0.115 1.544  0.127 
Ethnicity  -0.123 4.606  -0.002   -0.027  0.979 
Education  0.100 0.648  0.011  0.155  0.878 
The regression of predictor variables onto the SkinDex-16 showed that fatigue distress 
was the only variable with a statistically significant relationship.  The variable of education was 
excluded from this analysis due to a lack of correlation with the SkinDex-16 instrument.  The 
positive correlation between the SkinDex-16 and fatigue distress shows that as skin 
manifestations become more bothersome, fatigue distress increases (Table 15).  
Table 15. Regression of Predictor Variables onto SkinDex-16 (n=75) 
Variable    B     Standard error of B       t  P 
Stage of disease            5.201  5.017  0.090   1.037  0.304 
Depressive symptoms   -0.202  0.369  -0.085  -0.549  0.585 
Anxiety   0.381  0.316  0.196  1.205  0.232 
Spirituality      -0.189  0.181  -0.202  -1.042  0.301 
Fatigue distress  0.177   0.083  0.347  2.128  0.037 
Age   -0.359   0.187  -0.185  -1.923  0.059 
Gender   7.540   4.527  0.134  1.666  0.101 
Ethnicity  -4.825   5.752  -0.077  -0.839  0.405 
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Chapter 5 Discussion, Implications and Conclusions 
This chapter discusses the findings presented in Chapter 4.  The sample and descriptive 
data are interpreted.  The influence of the predictor variables on quality of life and the 
relationship among the SkinDex instruments and the predictor variables also are discussed. 
Sample 
The sample involved 75 participants with cutaneous T cell lymphoma (CTCL).  Most 
participants were male with stage IA disease.  The mean age of the participants was noted to 
be approximately 62 years, which supports prior research that CTCL is a disease of a slightly 
older population.  However, the age range from 24-88 years reinforces that CTCL can affect 
anyone along the age spectrum.  A power analysis was conducted prior to data collection, and a 
sample size of 83 was recommended.  This was calculated where the Pearson’s correlation 
coefficient was 0.3 and the test of significance assumed alpha 0.05, with power 0.80.  The 
sample size dictated by the power analysis was not achieved due to a short recruitment time 
and a single researcher available to recruit participants.  Even though the goal sample size of 83 
was not obtained, the sample size of 75 produced statistically significant results.  
Descriptive Data 
The mean of the CES-D, which evaluates depressive symptoms, was noted to be 11 on a 
scale of 0 to 60.  It has been documented that a score of 16 or higher requires further 
evaluation for the presence of major depression (DSM-IV, 2004).  Furthermore, a score of 23 or 
greater may indicate probable depression.  The mean score in the CTCL population was much 
lower than either of these thresholds, indicating that depressive symptoms were not prevalent 
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or severe in this sample.  Some of this variability may be due to the fact that most participants 
(62.6%) had low stage disease (< stage IIA) and only 36% had advanced stage disease (> 
stage IIB).  Given that more than half of this group had early stage disease, the low mean 
score on the CES-D should not be surprising and may not be representative of the patients with 
higher stage disease (>stage IIB). 
The state portion of the state-trait anxiety inventory was used to evaluate the presence 
of anxiety in the sample.  Their mean score was 34.73, while the scores can range between 20 
and 80.  The mean result demonstrates that on average anxiety is low in this group.  A majority 
of the participants in the sample (47 of 75) had disease that required minimal to no treatment.  
It would be expected that an incurable disease would cause an increase in the amount of 
anxiety experienced by participants; however, the results revealed a contrary outcome.  The 
realization that the treatment regimen for these participants is not invasive and should not have 
an impact on their normal activities of daily living, may lead to a lower level of anxiety for most 
this sample or may allow them to use the defense mechanism of denial. 
The presence of fatigue in cancer patients has been well documented, and is reported to 
affect approximately 75% of cancer patients (Yennurajalingam, Palmer, Zhang, Poulter, & 
Brurera, 2008).  It has also been documented in the CTCL population with higher levels of 
fatigue found in patients with higher stage of disease (Demierre et al, 2005).  The cancer 
related fatigue distress scale (CRFDS) has been validated and utilized to evaluate how 
distressing fatigue can be for patients with cancer.  Most patients reported the presence of 
fatigue (n=52) but few reported a high level of distress related to the fatigue.  The mean score 
for fatigue distress was 48.6, much less than the highest score of 200.  These results 
demonstrate that high levels of fatigue distress were not frequently reported by this sample. 
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 Quality of life was moderately high with the mean score for the sample being reported 
as 68.9 on a scale of 0 to 100.   This mean score demonstrates that the sample has been able 
to maintain a very good quality of life even though they have a diagnosis of an incurable 
cancer.  Again, these results may be more representative of participants with minimal disease 
burden and therefore, minimal to no need for systemic treatment.  It is expected that patients 
with more advanced disease would experience a decrease in their quality of life.  This may be 
attributed to symptoms of disease, side effects of treatment, or the physical and mental burden 
of treatment. Overall, these results seem to indicate that the quality of life for the participants 
in this group is good.  Future studies should include patients with more advanced disease. 
 The variable of spiritual well-being was measured by the FACIT-Sp and revealed a mean 
score of 118.49 on a scale of 0 to 156.  So, the results from this study demonstrate that 
participants in the sample, who were predominantly Christian, had moderately high reports of 
spiritual well-being.  It has been reported that high levels of spiritual well-being are associated 
with higher levels of quality of life for cancer patients (Bredle, et al, 2011). 
    All of the instruments used in this study have been validated and shown to be reliable 
(Dirmaier et al., 2004; Chren et al., 1997; Chren et al., 2001; Schroevers et al., 2000; 
Spielberger et al., 1983; Cella, et al. 1993; Bredle, et al, 2011; Holley, 200).  The reliabilities for 
each measurement instrument utilized in this study were calculated and most demonstrated 
high reliabilities.  All instruments demonstrated alpha coefficients greater than 0.90 with the 
exception of the FACIT-Sp, which demonstrated an alpha coefficient of 0.77.  Although lower 
than the other instruments, this alpha of 0.77 is certainly acceptable. The CTCL population has 
not been studied extensively; therefore, the results of the reliability coefficients are important in 
this population to lay a foundation for future research.   
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 Each of the items on the SkinDex-29 instrument was evaluated to determine which 
cutaneous related symptoms were the most frequently reported.  The number of responses 
included participants who answered “rarely”, “sometimes”, “often”, and “all the time”.  The 
most frequent symptoms reported were skin itching and skin irritation.  The least frequently 
reported symptoms included how the disease affected interaction with others and skin bleeding.  
It was not stratified to evaluate how many participants answered at each of the four levels.  
This would be helpful in determining how much each symptom affected the participants and 
should be included in future research.  
Influence of Predictor Variables on Quality of Life 
 Correlations of the predictor variables were conducted prior to the regression to 
evaluate if there were relationships worthy of investigating.  The variables of gender and 
ethnicity (white vs. non-white) were evaluated using an independent samples t-test.  This 
method revealed non-significant differences among these groups on their QOL scores and they 
were excluded from the subsequent regression analysis.  Stage of disease was evaluated using 
a Spearman correlation and was found to have a significant relationship with the outcome 
variable QOL.  Bivariate correlations were calculated between the continuous variables and 
QOL.  The variables that demonstrated a statistically significant relationship with QOL were 
included in the regression analysis.  Ethnicity and gender did not demonstrate significant 
correlation with QOL and therefore, were not included in the regression analysis. 
 The regression analysis revealed that only depressive symptoms (p=0.039) and stage of 
disease (p=0.002) were identified as predictors of QOL in the sample.  The influence of 
depressive symptoms on QOL in patients with a diagnosis of incurable cancer has been 
demonstrated in previous research (Warmenhoven et al., 2011).  The concurrent occurrence of 
multiple somatic symptoms, especially when they are uncontrolled, has been found to be 
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predictive of the development of depressive symptoms (Chen & Chang, 2004; Lloyd-Williams, 
Shiels, Taylor, and Dennis, 2009). Participants with advanced stage of CTCL would be expected 
to have worse QOL as opposed to participants with lower stage of disease because they have 
more cutaneous and quite possibly systemic symptoms (Weiss et al, 2002, Gelfand et al, 2004). 
Research has shown that in patients with chronic lymphocytic leukemia, another type of 
indolent disease, good QOL is preserved until they experience an increase in the frequency of 
symptoms (Shanafelt et al, 2007).  Patients diagnosed with stage I CTCL have been shown to 
have a normal life span and may not be as affected by the psychological side effects of having 
an incurable diagnosis (Demierre et al, 2006).  This lends support to the lack of influence of 
anxiety as a predictor of QOL in this study.  Anxiety would be expected to be a significant 
predictor of QOL in a population with more advanced disease. 
Spiritual well-being did not exhibit a significant relationship as a predictor of QOL.  
These findings might have been different if the sample included more participants with 
advanced stage disease.  It has been shown that an increased level of spiritual well-being is 
associated with a lower level of depression experienced by patients with cancer (Bredle, et al, 
2011); thus, QOL would be expected to be improved by decreased depression and improved 
spiritual well-being. 
Fatigue distress was also not identified as a predictor of QOL.  Again, this finding would 
be expected in this sample with so many participants having low stage disease.  The majority of 
these patients (n= 54) were receiving non-invasive therapy in the form of topical creams used 
as needed or exposure to ultraviolet light on a weekly basis and reported low levels of fatigue 
distress.  It is known that patients with advanced stages of cancer experience fatigue, either as 
a side effect of the disease process or as a side effect of the treatment of their cancer 
(Demierre et al, 2006).  Future studies should focus on patients with higher stage disease. 
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Surprisingly, the SkinDex-29, a dermatologic specific measure of QOL, did not exhibit a 
significant influence as a predictor of QOL in this sample.  Previous research has shown that 
dermatological symptoms, more specifically pruritis, are the most distressing symptoms for 
patients with CTCL (Demierre et al, 2005).  The results of this study speak to how important 
stage of disease is as a predictor of QOL.   
Relationship Among The SkinDex-16, SkinDex-29, and the Predictor Variables 
 One of the specific aims of the study was to evaluate which dermatologic specific 
measurement tool was more appropriate to use in the study of CTCL patients.  The SkinDex-29 
has been used more frequently in dermatologic studies.  It measures how frequently symptoms 
are experienced.  The SkinDex-16 was derived from the SkinDex-29 and measures how severe 
the symptoms are when they are experienced.  In order to establish the relationship between 
these two instruments bivariate correlations were conducted between each of the subscales and 
the total score for each instrument.  As presented in Chapter 4, the Pearson correlation 
coefficient between the two scales was high (r=0.86; p<0.001).  This finding is not surprising 
given that the SkinDex-16 was derived from the SkinDex-29, and provides additional evidence 
of construct validity for the newer Skindex-16.  In addition, the subscales of the shortened 
Skindex-16 were strongly correlated with the matching subscales of the Skindex-29 (r=0.76-
0.86; p<0.001).  This offers further support for the construct validity of the Skindex-16.     
 Bivariate correlations were conducted among the predictor variables and each SkinDex 
measurement instrument.  Because the correlations between the subscales and the total scores 
of the SkinDex-16 and SkinDEx-29 were so high, only the total scores were used for the 
correlation calculations.  Significant correlations were noted among anxiety, depressive 
symptoms, spirituality, fatigue distress, age and both the SkinDex-29 and SkinDex-16.  All 
variables with significant correlations with the SkinDex instruments were included in a 
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regression analysis.  Level of education was significantly correlated with SkinDex-29 but not 
with SkinDex-16 therefore, it was omitted from the SkinDex-16 regression analysis.  
Independent samples t-tests were conducted for the categorical variables of gender, ethnicity, 
and stage of disease.  The t-test results demonstrated statistically significant relationships and 
these variables were ultimately included in the regression analysis.   
 The predictor variables were regressed onto the SkinDex-16 and SkinDex-29 to evaluate 
for significant relationships.  The variables of depressive symptoms, age, and fatigue distress 
were shown have significant relationships with the SkinDex-29.  It has been shown that as age 
increases participants are less likely to report symptoms when compared to a younger 
population who has been diagnosed with a very visible skin condition (Gelfand et al, 2004).  
  Depressive symptoms demonstrated a significant positive relationship with the SkinDex-
29.  These results are not surprising due to the fact that as dermatologic symptoms increase, 
the level of depressive symptoms would also increase.  Any indication of disease progression in 
a patient with a cancer diagnosis would enhance an expectation of an increase in depressive 
symptoms.  Also, fatigue distress demonstrated a positive correlation with Skin-Dex-29.  Fatigue 
is a known side effect of cancer and the treatment for cancer and is commonly associated with 
depression.  As disease progresses, it would be expected that fatigue would increase also.  
When fatigue interferes with activities of daily living, or normal activities it causes distress for 
the participants.  Therefore, the positive correlation between fatigue distress and increased 
dermatologic symptoms would be expected.   It’s important to note that older patients are 
typically retired and have the ability to rest when they feel fatigue.  A younger population that 
may be responsible for maintaining a job and caring for a family may find the fatigue to be 
more distressing.   
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In the regression analysis of the predictor variables onto SkinDex-16, the only variable 
that demonstrated a significant relationship was fatigue distress.  This positive relationship 
reveals that as the severity of the dermatologic symptoms increases, fatigue distress increases 
as well.   Ultimately, when comparing The SkinDex-16 and SkinDex-29 for usefulness, no 
difference was identified.  The two measurement tools were closely correlated and appeared to 
measure the same constructs.  Thus, the shorter tool, the Skindex-16, may be more useful in a 
busy clinical practice.  However, in research it may be more suitable to utilize the Skindex-29 as 
it offers more variety in the information obtained.   
Implications of the Study 
 The results of this study have identified significant predictors of QOL and identified 
relationships among variables that evaluate the effect of cutaneous symptoms and how they 
contribute to the QOL.  Some of the measurement instruments utilized in this study were 
closely correlated and may have measured some of the same constructs.  Factors that may 
have influenced the outcome of the study included when patients have their disease staged.  
Patients are staged at their initial visit to an oncologist.  As they receive treatment for their 
disease, their stage of disease improves, thereby improving their quality of life. The initial stage 
at diagnosis follows the patient through their treatment trajectory and never changes even if 
their clinical stage improves or worsens.  These are factors that need to be noted when 
evaluating results based on stage of disease.  Mean scores were reported, meaning that 
although some of the participants experienced little impact of depressive symptoms or anxiety, 
there were some participants who were more impacted by these symptoms.  Evaluating for 
predictors that influence the QOL helps us to better understand the needs of the patients 
afflicted with CTCL.  The importance of studying the QOL of the CTCL patients lies in the fact 
that we as nurses can assist in alleviating some of the symptoms experienced by the patients, 
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thereby improving their QOL.  Further study is warranted in developing interventions to assist in 
the preservation of QOL. 
Limitations of the study include that there was only one researcher to obtain informed 
consent and administer the compiled surveys for completion.  This may have contributed to 
eligible participants not being approached for participation in the study.  A significant number of 
participants (n=47) had low stage disease, that may not require any specific therapy.  There 
was an under-representation of participants with advanced stage disease, which likely affected 
the results.  Most of the participants were white, lending to an under-representation of minority 
groups.  Due to the number of participants that had stage IIA disease or less, these results may 
represent information for patients with low stage disease.  It might be expected that results 
may be significantly different when these measurement instruments are administered to a 
higher population of patients with advanced stage disease (stage IIB and higher). 
A strength of the study is that this disease state makes up less than 3% (approximately 
1500-3000 patients) of non-Hodgkin lymphoma diagnoses every year, yet 75 participants 
agreed to complete the surveys investigating how their disease affects their quality of life.  It 
was wonderful to have so many willing participants from a rare and under-studied disease 
state.  
Implications for nursing are that nurses offer a great wealth of knowledge and education 
in managing side effects of cancer and its treatment.  Patients with skin diseases are at high 
risk of infection, especially if they are exhibiting high symptom burden and suffering from 
pruritis.  Nurses can provide education to patients, colleagues, and students regarding good 
skin care, effective management of the side effects of this disease and prevention of infection. 
In the clinical setting, education is important to putting the patient at a psychological advantage 
when coping with an incurable disease.  Providing support both mentally and physically is 
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important for providing adequate care for patients with CTCL.  The integration of effective 
nursing interventions is important in the care of patients with chronic skin conditions and this is 
an area where research can be expanded.  
Conclusions 
In conclusion, the results of this study revealed that stage of disease and the presence 
of depressive symptoms influenced the QOL of patients with CTCL.  This is expected because 
patients with later stage of disease would have a worse QOL.  Also, participants with an 
increased number of depressive symptoms would have a worse QOL.  These findings have been 
well established in the literature and are echoed in the results of this study.  The significant 
influence of depressive symptoms may be alleviated with the implementation of support groups 
for patients diagnosed with CTCL.  Assessing for these symptoms in the clinical setting may also 
identify patients who are more affected.  Early identification would allow the healthcare provider 
to refer patients experiencing more severe symptoms of depression for further evaluation by a 
specialist. 
The SkinDex-16 and the SkinDex-29 were evaluated to determine which would be better 
suited for use in this population.  The SkinDex-16 is shorter and less burdensome for patients to 
complete therefore, it is reasonable for this measure to be used in future studies of this 
population.   Stage of disease also demonstrated a significant relationship with QOL.  Evaluating 
dermatologic symptoms experienced by patients may be an indication that the disease is 
progressing and may need supportive care and medical intervention.  Supportive care in the 
form of moisturizing creams can be initiated by the nurses in the clinical setting.  Promotion of 
good skin care will help decrease the desire to itch and maintain the integrity of the skin, which 
will decrease the risk of a life threatening infection.  
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Future studies could be conducted to include a larger sample of participants with 
advanced (stage IIB and higher) disease.  This was designed as an exploratory study.  The 
patients completed surveys evaluating for anxiety, depressive symptoms, fatigue distress, 
spiritual well-being, QOL, and dermatologic symptoms.  It is known that some of these 
instruments measure similar constructs.  It is plausible that multi-colinearity may account for 
the lack of significance of anxiety or fatigue distress on QOL.  In future studies, it would be 
helpful to focus on fewer variables to highlight the influence on QOL in CTCL patients.  In 
addition, studies to incorporate nursing interventions for skin care and wound care 
management would also be beneficial.  
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Skindex29 
MMChren,1996 
DERMATOLOGY SURVEY 
This survey concerns the skin condition which has bothered you the most during 
the past four weeks.       
Appendix B:  Measurement Instruments




Date: 
Patien.,..t :::ID::-: --
CES-DSCALE 
~-:le 1he number for each statement 'N!hiich best describes how often you ·felt or b'~hav:scl this 
~ DURING THE PAST WEEK r'J -
Rarely or Occasionally 
None of Some or . ora 
the Time a Little of Moderate Most or All 
(Less the Time Amount of of the Time 
DURING THE PAST WEEK: than {1-2 days) Time (5-7 days) 
1 day) (3-4 days) 
1. I was bothered by things that usually 0 1 2 3 don't bother me. 
2. I did not feel like eating; my appetite was 0 1 2 3 poor. 
3. I felt that I could not shake off the blues 0 1 2 3 even with he!!>_ from my family or friends. 
4. I felt that I was just as good as other 0 1 2 3 people. 
5. I had trouble keeping my mind on what I 0 1 2 3 was doing. 
6. I felt depressed. 0 1 2 3 
7. I felt that everything I did was an effort. 0 1 2 3 
I I felt hopeful about the future. 0 1 2 3 
9. I thought my life had been a failure. 0 1 2 3 
10. I felt fearful. · o 1 2 3 
11. My sleep was restless. 0 1 2 3 
12. I was happy. 0 1 2 3 
13. I talked less than usual. 0 1 2 3 
14. lfelt lonely. 0 1 2 3 
15. People were unfriendly. 0 1 2 3 
16. I enjoyed life. 0 1 2 3 
:-1Z. 1 hacLccying spells~ .. _ 0 
- -
1 2 
--
3 
--
·-
-- - --
1R. I felt sad. 0 1 2 3 
1l:;. I felt that people disliked me. 0 1 2 3 
20. I could not get "going". 0 1 2 3 
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mt nd garden 
SELF-EVALUATION QUESTIONNAIRE 
STAI Form Y-1 
Please provide the following information: 
Name. ____ _____ _ ________ Date. _ _ ___ _ s _ _ 
Age, _ ___ ___ _ Gender (Circle) M F T __ 
DIRECTIONS: 
A number of statements which people have used to describe themselves are given below. 
Read each statement and then circle the appropriate number to the right of the statement 
to indicate how you feel right now, that is, at this moment. There are no right or wrong 
answers. Do not spend too much time on any one statement but give the answer which 
seems to describe your present feelings best. 
I. I feel calm ...... ............... .................................................................................... .......... ......... .. 
2. I feel secure ....................................................................................................... ................... . 
3. I am tense ................................................... ......................... ........................................ .......... . 
4. I feel strained ........ .. .... ............... ......................................................................... ............... .. .. 
5. I fee l at ease ........................................................................................................................... I 
6. I feel upset ............................................................................. ............................................... . 
7. I am presently worrying over possible misfortunes ..... ..................... ....... ....................... .... .. 
8. I feel satisfied ............ .... ................ ............... ......................................................................... 1 
9. I feel frightened ........................................................................................ ............................ . 
I 0. I feel comfortable ......................................... ................. .................... ................................... . 
II . I feel se lf-confident ....................................... ............ ...................................... .... ................ .. 
12. I feel nervous ................... .... ...................... .... ...... ..................... ....... ......... ... ....... .......... ...... . .. 
13. I am jittery ..................................... ......... ............................................ .................................. . 
14. I feel indecisive ......................................... ...... .......................................... ... ....................... .. 
15. I am re laxed ............... ............................. .. .... ................... .. .......... .............. .................. ......... . 
16. I feel content ....................................................................................... ....................... ........... . 
17. I am worried ........................................ .................. ............................................. .................. . 
_-= ::=rs::J=teel-eentilsed .... , .................. , ............. ......................... .................................... .................... . 
19. I feel steady ..................... ...................................................................................................... 1 
20. I fee l pleasant ............ ........................................................................................................... . 
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DERMATOLOGY SURVEY 
 
 
 
 
 
This survey concerns the skin condition which has bothered you the most 
during the past week. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

